IP Library Granted Patent US 8,546,450
Granted Patent B1
US 8,546,450 · App. 12/459,998 · Granted Oct 1, 2013

Treatment of pain with topical diclofenac compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,546,450
App. No.
12/459,998
Granted
Oct 1, 2013
Kind
B1
Abstract

The field involves compositions useful for pain relief, including diclofenac solution and gel formulations, in particular methods of use thereof, articles of manufacture and kits that provide novel preclinical, clinical and other information to users.

Claims (28)

1. A method for treating a patient with combination therapy, said combination therapy comprising:

administering a therapeutically effective amount of an oral NSAID; and

applying a topical diclofenac preparation to a knee of said patient to treat osteoarthritis of the knee of said patient, wherein said topical diclofenac preparation comprises a therapeutically effective amount of a diclofenac salt and 40-50% w/w dimethyl sulfoxide,

wherein the therapeutically effective amount of oral NSAID is the amount required to achieve a therapeutic effect in the absence of applying a topical diclofenac preparation.

2. The method according to claim 1 , wherein the patient is treated for severe knee pain.

3. The method according to claim 1 , wherein the patient is treated for breakthrough knee pain.

4. The method according to claim 1 , further comprising:

conducting periodic laboratory evaluations regarding said patient and the combination therapy.

5. The method according to claim 1 , wherein said diclofenac preparation comprises about 45.5% w/w dimethyl sulfoxide.

6. The method according to claim 1 , wherein said diclofenac preparation further comprises ethanol, propylene glycol, glycerine, and water.

7. The method according to claim 1 , wherein said therapeutically effective amount of diclofenac comprises a pharmaceutically acceptable salt of diclofenac selected from a sodium salt, a potassium salt, a diethylamine salt, or an epolamine salt.

8. The method according to claim 1 , wherein said therapeutically effective amount of diclofenac is 1.5% w/w diclofenac sodium.

9. The method according to claim 1 , wherein said oral NSAID is a member selected from the group consisting of a COX-2 selective NSAID, diclofenac, tenoxicam, meloxicam, celecoxib, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, nabumetone, naproxen, oxaprozin, piroxicam, sulindac, and tolmetin.

10. A method for applying topical agents to a knee of a patient with pain, said method comprising:

applying a first medication consisting of a topical diclofenac preparation to an area of the knee of said patient to treat osteoarthritis of the knee of said patient, wherein the topical diclofenac preparation comprises a therapeutically effective amount of a diclofenac salt and 40-50% w/w dimethyl sulfoxide;

waiting for the treated area to dry;

subsequently applying a sunscreen, or an insect repellant to said treated area after said treated area is dry, wherein said step of applying a first medication does not enhance the systemic absorption of the subsequently applied sunscreen, or insect repellant; and

wherein said subsequent application occurs during a course of treatment of said patient with said topical diclofenac preparation.

11. The method according to claim 10 , wherein said diclofenac preparation comprises about 45.5% w/w dimethyl sulfoxide.

12. The method according to claim 10 , wherein said therapeutically effective amount of diclofenac is 1.5% w/w diclofenac sodium.

13. The method according to claim 10 , wherein said diclofenac preparation further comprises ethanol, propylene glycol, glycerine, and water.

14. The method according to claim 10 , wherein said therapeutically effective amount of diclofenac comprises a pharmaceutically acceptable salt of diclofenac selected from a sodium salt, a potassium salt, a diethylamine salt, or an epolamine salt.

15. The method according to claim 10 , wherein said step of subsequently applying comprises subsequently applying said sunscreen.

16. The method according to claim 15 , wherein said sunscreen comprises oxybenzone.

17. The method according to claim 10 , wherein said step of subsequently applying comprises subsequently applying said insect repellant.

18. The method according to claim 17 , wherein said insect repellant comprises N,N-diethyl-m-toluamide (DEET).

19. The method according to claim 17 , wherein said insect repellant comprises 2,4 D dimethylamine salt (2,4 D).

20. The method according to claim 14 , wherein said therapeutically effective amount of diclofenac comprises diclofenac sodium.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Oct 6, 2023
From: CITIBANK, N.A.
To: HORIZON THERAPEUTICS IRELAND DAC (SUCCESSOR IN INTEREST TO HORIZON PHARMA SERVICES LIMITED); HORIZON THERAPEUTICS IRELAND DAC (FKA HORIZON PHARMA IRELAND LIMITED); HORIZON THERAPEUTICS USA, INC. (FKA HORIZON PHARMA USA, INC.); HZNP LIMITED
Reel/Frame 065153/0953 →
RELEASE OF SECURITY INTEREST Recorded May 17, 2023
From: PALADIN LABS INC.
To: NUVO RESEARCH INC.
Reel/Frame 063695/0543 →
CHANGE OF NAME Recorded Oct 27, 2022
From: HZNP MEDICINES LLC
To: HZNP FINANCE LIMITED
Reel/Frame 061562/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2022
From: HZNP FINANCE LIMITED
To: HORIZON THERAPEUTICS IRELAND DAC
Reel/Frame 061563/0467 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2018
From: HZNP LIMITED
To: HZNP MEDICINES LLC
Reel/Frame 046455/0582 →
SECURITY INTEREST Recorded May 7, 2015
From: HZNP LIMITED
To: CITIBANK, N.A.
Reel/Frame 035591/0061 →
RELEASE OF SECURITY INTEREST Recorded Dec 2, 2014
From: PALADIN LABS INC.
To: NUVO RESEARCH INC.
Reel/Frame 034314/0041 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2014
From: NUVO RESEARCH INC.
To: HZNP LIMITED
Reel/Frame 034068/0184 →
GENERAL SECURITY AGREEMENT Recorded Aug 20, 2012
From: NUVO RESEARCH INC.
To: PALADIN LABS INC.
Reel/Frame 028816/0225 →